|Ms. Laura M. Clague CPA||CFO & Sr. VP||592.98k||N/A||1959|
|Dr. William E. Rote||Sr. VP and Head of R&D||622.76k||N/A||1963|
|Dr. Noah L. Rosenberg||Chief Medical Officer||831.49k||N/A||1967|
|Dr. Eric M. Dube Ph.D.||Pres, CEO & Director||N/A||N/A||1973|
|Chris Cline CFA||VP of Investor Relations & Corp. Communications||N/A||N/A||N/A|
Retrophin, Inc., a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. The company's product candidates also consist of Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; CNSA-001, an orally bioavailable proprietary form of sepiapterin that is in phase II clinical trial for the treatment of phenylketonuria; and liquid ursodeoxycholic acid, a liquid formulation of ursodeoxycholic acid for the treatment of primary biliary cholangitis. The company has a cooperative research and development agreement with National Center for the identification and development of therapeutics for Alagille syndrome. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.
Retrophin, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 5. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 2; Compensation: 9.